Graft versus host disease (GVHD) is a condition that might occur after an allogeneic transplant. In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body.
Treatment often cannot provide complete healing and it takes a long time to cure the disease. The Spanish research group has developed a new therapy using mesenchymal stromal cells which improves and facilitates the processing and accessibility of the donor tissue.
Mesenchymal stromal cells are commonly known for their immunomodulatory effects, hence their interest in treating GVHD after a transplant of hematopoietic stem cells.
The Spanish research group has developed a kit composed of an immunosuppressive agent and mesenchymal stromal cells of adipose tissue.
This method helps to reduce the unwanted effects of it, such as the high probability of relapse, infections or delay for recovering the immune system.
The research group is looking for the following collaboration:
-License agreement: framework of authorizing the interested parties to use the technology.
-Technical cooperation agreement: to collaborate with other research teams, companies or foundations.